143 related articles for article (PubMed ID: 37596982)
1. Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children.
van der Laan LE; Hesseling AC; Schaaf HS; Palmer M; Draper HR; Wiesner L; Denti P; Garcia-Prats AJ
J Antimicrob Chemother; 2023 Oct; 78(10):2481-2488. PubMed ID: 37596982
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
[TBL] [Abstract][Full Text] [Related]
5. Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children.
Bélard S; Ramharter M; Kurth F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD009568. PubMed ID: 33289099
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Waalewijn H; Chan MK; Bollen PDJ; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Sarfati T; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Moore CL; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2022 May; 9(5):e341-e352. PubMed ID: 35189082
[TBL] [Abstract][Full Text] [Related]
7. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
[TBL] [Abstract][Full Text] [Related]
9. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
[TBL] [Abstract][Full Text] [Related]
12. Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling.
Zou Y; Nedelman J; Lombardi A; Pappas F; Karlsson MO; Svensson EM
Clin Pharmacokinet; 2022 Nov; 61(11):1585-1593. PubMed ID: 36180816
[TBL] [Abstract][Full Text] [Related]
13. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
Abdulla S; Amuri B; Kabanywanyi AM; Ubben D; Reynolds C; Pascoe S; Fitoussi S; Yeh CM; Nuortti M; Séchaud R; Kaiser G; Lefèvre G
Malar J; 2010 Sep; 9():253. PubMed ID: 20815879
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
[TBL] [Abstract][Full Text] [Related]
15. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
16. Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.
Purchase SE; Garcia-Prats AJ; De Koker P; Draper HR; Osman M; Seddon JA; Schaaf HS; Hesseling AC
Pediatr Infect Dis J; 2019 Jun; 38(6):608-610. PubMed ID: 30550511
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis.
Bjugård Nyberg H; Draper HR; Garcia-Prats AJ; Thee S; Bekker A; Zar HJ; Hooker AC; Schaaf HS; McIlleron H; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871093
[TBL] [Abstract][Full Text] [Related]
18. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
Chabala C; Turkova A; Hesseling AC; Zimba KM; van der Zalm M; Kapasa M; Palmer M; Chirehwa M; Wiesner L; Wobudeya E; Kinikar A; Mave V; Hissar S; Choo L; LeBeau K; Mulenga V; Aarnoutse R; Gibb D; McIlleron H
Clin Infect Dis; 2022 May; 74(10):1767-1775. PubMed ID: 34420049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
